- Investing.com
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Metrics to compare | AZTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZTRPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −2.0x | −0.6x | |
PEG Ratio | 0.00 | −0.04 | 0.00 | |
Price/Book | 2.2x | 3.5x | 2.6x | |
Price / LTM Sales | 9.2x | 16.6x | 3.3x | |
Upside (Analyst Target) | - | 184.9% | 44.5% | |
Fair Value Upside | Unlock | 13.5% | 6.0% | Unlock |